Uptake of hepatitis C direct-acting antiviral treatment in China: a retrospective study from 2017 to 2021

Uptake of hepatitis C direct-acting antiviral treatment in China: a retrospective study from 2017 to 2021

Abstract Background Direct-acting antivirals (DAAs) for hepatitis C treatment in China became available since 2017. This study expects to generate evidence to inform decision-making in a nationwide scale-up of DAA treatment in China. Methods We described the number of standard DAA treatment at both...

Full description

Bibliographic Details
Main Authors: Xinyu Du, Jiarun Mi, Hanchao Cheng, Yuanyuan Song, Yuchang Li, Jing Sun, Polin Chan, Zhongdan Chen, Simon Luo
Format: Article
Language:English
Published: BMC 2023-03-01
Series:Infectious Diseases of Poverty
Subjects:
Direct-acting antiviral
Hepatitis C
Treatment
Universal health insurance
China
Online Access:https://doi.org/10.1186/s40249-023-01081-4

Internet

https://doi.org/10.1186/s40249-023-01081-4

Similar Items